Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. In addition, the company develops proprietary diagnostic and therapeutic products leveraging exosome technology; and provides development services for hospitals. The company has a strategic partnership with Weill Cornell Medical College to co-develop bio-production and standardization procedures for chimeric antigen receptor (CAR)-T Therapy; GensKey Medical Technology Co. Ltd. to co-develop and commercialize point-of-care, rapid detection antibody tests to identify whether a patient has been exposed to and has developed antibodies against SARS-CoV-2; GE Healthcare to enhance standardized automation and bio-production for cellular medicines; and HydroPeptide, LLC to co-develop and commercialize various clinical-grade, exosome-based cosmeceutical and orthopedic products, as well as research agreement with Massachusetts Institute of Technology to develop CAR technology. It also has a collaboration agreement with the UPMC Hillman Cancer Center to advance the clinical development and production of CAR therapies using FLASH CAR technology. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: avalon-globocare.com
Goal of Partnership is to expand Avalon's R&D pipeline to include innovative companion diagnostics in association with the company's ongoing and future cellular immunotherapy clinical programs Appoints Dr. Hongxing Liu, a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board to further strengthen Avalon's companion diagnostics development capabilities FREEHOLD, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has signed a memorandum of understanding (MOU) with Lu Daopei Hematol
VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a leading global developer and provider of cellular communications solutions for enterprise customers, today announces the appointment of Peter Goldstein, currently a Siyata Board member, as the Chairman of its Board of Directors. In addition, Luisa Ingargiola, who has extensive experience on public company boards and in the capital markets, has been appointed to the Board of Directors effective as of the shareholders meeting on February 23, 2021. “Peter’s many years in working with emerging growth, publicly traded companies is paramount to our asking him to
SC 13D/A - Avalon GloboCare Corp. (0001630212) (Subject)
8-K - Avalon GloboCare Corp. (0001630212) (Filer)
10-Q - Avalon GloboCare Corp. (0001630212) (Filer)
8-K - Avalon GloboCare Corp. (0001630212) (Filer)
D - Avalon GloboCare Corp. (0001630212) (Filer)
8-K - Avalon GloboCare Corp. (0001630212) (Filer)
8-K - Avalon GloboCare Corp. (0001630212) (Filer)
ARS - Avalon GloboCare Corp. (0001630212) (Filer)
DEF 14A - Avalon GloboCare Corp. (0001630212) (Filer)
8-K - Avalon GloboCare Corp. (0001630212) (Filer)
PRE 14A - Avalon GloboCare Corp. (0001630212) (Filer)
Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 Symbol Change Better Reflects Avalon's New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced that its ticker symbol will change on the NASDAQ Stock Exchange from "AVCO" to "ALBT" at the open of market trading on Thursday, November 10, 2022. David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, "Yesterday we announced a transformative acquisition of Laboratory Services MSO, LLC,
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a private placement of $15 million of Avalon preferred stock, convertible at a floor of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 FREEHOLD, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company")(NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and
Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare, will be presenting at the 15th annual LD Micro Main Event being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.Presentation details:Event:LD Micro Main Event XVDate:Wednesday, October 26th, 2022Time:4:00 PM PT/ 7:00 PM ET Register to watch the virtual presentation here.Management will be available for one-on-one meetings
FREEHOLD, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today provided an update regarding the Company's intellectual property portfolio featuring its QTY protein code technology. The Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) and covers seven claims related to the technology. The Company also submitted a new patent application to the USPTO related to
FREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new study applying artificial intelligence (AI) enhanced protein design "QTY Code" technology. The method is expected to accelerate development of therapeutic monoclonal antibodies to treat cancer. The research demonstrates a novel method for quickly predicting the design of so-called "water-loving" or hydrophilic variant structures of the 14 glucose transport membrane proteins in cells, which allows researchers to study the proteins more easily in water. Glucose transport membrane proteins are deregu
FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer, of Avalon GloboCare, will be presenting at the Jefferies 2022 Healthcare Conference which is being held on June 8–10, 2022 in New York City. Management is scheduled to present on Friday, June 10, 2022, at 12:45 PM ET. Management will also be available for one-on-one meetings with investors during the conference. About Avalon GloboCare Corp.Avalon GloboCare Corp. (NASDAQ:AVCO) is a clinical-st
Goal of Partnership is to expand Avalon's R&D pipeline to include innovative companion diagnostics in association with the company's ongoing and future cellular immunotherapy clinical programs Appoints Dr. Hongxing Liu, a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board to further strengthen Avalon's companion diagnostics development capabilities FREEHOLD, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has signed a memorandum of understanding (MOU) with Lu Daopei Hematol
Co-inventors are leading international universities and cellular therapy developers Patent applications cover three types of cellular therapies and related technologies FREEHOLD, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. Patents were filed with the U.S. Patent and Trademark
Leveraging Avalon's existing Flash-CARTM technology platform to develop next-generation mRNA-based CAR-NK cellular therapeuticsClinical development of CAR-NK cell therapy planned in collaboration with the Company's clinical partner, Lu Daopei Hospital, as a potential treatment for hematologic malignancies and other unmet medical areasAppoints Dongfang Liu, Ph.D., a world-class scientist and expert in CAR-NK technology, to Avalon's Scientific and Clinical Advisory Board FREEHOLD, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company is expanding its cellular immu
Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe Intended SenlangBio acquisition terminated, eliminating potential 80 million share issuance FREEHOLD, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a year-end business update. "We believe we have made significant progress in 2021, advancing our scientific and clinical programs focusing on immuno-oncology and cellular medicines," said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. "
4 - Avalon GloboCare Corp. (0001630212) (Issuer)
4 - Avalon GloboCare Corp. (0001630212) (Issuer)
4 - Avalon GloboCare Corp. (0001630212) (Issuer)
4 - Avalon GloboCare Corp. (0001630212) (Issuer)
4 - Avalon GloboCare Corp. (0001630212) (Issuer)
4/A - Avalon GloboCare Corp. (0001630212) (Issuer)
4/A - Avalon GloboCare Corp. (0001630212) (Issuer)
4 - Avalon GloboCare Corp. (0001630212) (Issuer)
Gainers Unique Fabricating, Inc. (NYSE:UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. TaskUs, Inc. (NASDAQ:TASK) shares jumped 37.2% to settle at $22.01 on Tuesday after the company reported better-than-expected Q3 results. The company also issued Q4 and FY22 sales guidance above analyst estimates. GrowGeneration Corp. (NASDAQ:GRWG) shares jumped 35.1% to close at $4.47 after the company reported better-than-expected Q3 sales. SkyWater Technology, Inc. (NASDAQ:SKYT) gained 31.6% to close at $11.37 after the company reported better-than-expected Q3 EPS and sales results. Groupon, Inc. (NASDAQ
Gainers IceCure Medical Ltd (NASDAQ:ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast cancer cryoablation procedures. TaskUs, Inc. (NASDAQ:TASK) shares climbed 37.1% to $21.99 after the company reported better-than-expected Q3 results. The company also issued Q4 and FY22 sales guidance above analyst estimates. Oportun Financial Corporation (NASDAQ:OPRT) gained 36.1% to $5.65 after the company announced upbeat Q3 results. GrowGeneration Corp. (NASDAQ:GRWG) shares climbed 29.9% to $4.30 after the company reported better-than-expected Q3 sales. SkyWater Technology, Inc. (NASDAQ:
Avalon GloboCare Corp (NASDAQ:AVCO) has agreed to acquire a 60% interest in Laboratory Services MSO LLC, a premier reference laboratory. What Happened: Total consideration for the acquisition will be $31 million, including $15 million in cash, $15 million in series B preferred shares, and $1 million payable after one year of the closing of the transaction The company paid a $5 million refundable cash advance with the signing of the definitive agreement. Additionally, Laboratory Services will have an earnout tied to 2022 and 2023 positive cash flow targets of up to $10 million, payable in cash and shares. At the closing, Sarah Cox, the Co-founder & CEO of Laboratory Services, will becom